Comparative Pharmacology
Head-to-head clinical analysis: PENTACEF versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTACEF versus ROCEPHIN.
PENTACEF vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic